Navigating T1D Risk Screening: Identifying Ideal Candidates, Understanding Autoantibodies, and Determining Timing for Rescreening

Following a couple of audience polling questions, Andrea Stallings, PA and her UCSD colleagues, comment on identifying suitable candidates for T1D screening, understanding autoantibodies involved in this condition, and determining when to rescreen those at risk for disease progression.

Related Content:

Empowering Early Intervention: Navigating Treatments for Delaying T1D Progression, Insights from UC San Diego HealthDiabetesInstitutional Insights

More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates

Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes

Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease